Proxalutamide Explained

Proxalutamide (developmental code name GT-0918) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals, inc., a subsidiary of Kintor Pharmaceutical Limited, for the potential treatment of COVID-19, prostate cancer, and breast cancer.[1] [2] [3] [4] [5] It was approved in Paraguay for the treatment of COVID-19 in July 2021, but has not been approved at this time in other countries.

Research

Prostate cancer

Proxalutamide is in phase III studies for mCRPC as monotherapy and in combination with abiraterone. In the United States, it is in phase II study as monotherapy for mCRPC.[6] [7]

Other indications

Proxalutamide is in phase Ic clinical trial in China.[8]

See also

Notes and References

  1. Web site: Proxalutamide - Suzhou Kintor Pharmaceuticals . AdisInsight . Springer Nature Switzerland AG.
  2. Tong Y, Chen C, Wu J, Yang J, Zhang H, Wu X, Duan Y, Gao W, Qian W, Niu X, Mi L . 6 . Proxalutamide (GT0918), a potent androgen receptor pathway inhibitor . Cancer Research. 74. 19 Supplement. 2014. 614. 0008-5472. 10.1158/1538-7445.AM2014-614.
  3. Tong Y, Chen C, Wu J, Zhang H, Wu X, Duan Y, Gao W, Niu X, Ma L, Guo C . Discovery of potent androgen receptor antagonists for treating CRPC and AR+ breast cancer . Cancer Research. 73. 8 Supplement. 2014. 2460. 0008-5472. 10.1158/1538-7445.AM2013-2460 .
  4. Applied Biology, Inc.. 2020-12-29. Anti-Androgen Treatment for COVID-19.
  5. News: 2021-01-11. EQS-News: Kintor's Proxalutamide (GT0918) COVID-19 Clinical Trial Shows Positive Re-sults in Treatment of Male and Female. en. Bloomberg.com. 2021-01-29.
  6. Web site: Product Pipeline . 2021-01-29. Kintor Pharmaceutical.
  7. Clinical Trials . Suzhou Kintor Pharmaceutical . 2020-03-13. An Extended/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of GT0918 in Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone or Enzalutamide . US .
  8. Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer. 2021-01-29 . Clinical trials. 24 September 2019.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Proxalutamide".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.